# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two di...
Reports new interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecula...